RIGEL PHARMACEUTICALS INC
RIGLNext catalyst
Olutasidenib
Targeted Therapy
Get an email about RIGL's next catalysts
Track RIGEL PHARMACEUTICALS (RIGL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 1 past
Olutasidenib Phase 2 Est. Readout
Estimated primary completion for Olutasidenib trial (NCT07032727) in Targeted Therapy. Topline data typically follows completion by weeks to months.
SourceOlutasidenib Phase 2 Est. Readout
Estimated primary completion for Olutasidenib trial (NCT06445959) in Mutant IDH1 Inhibitor Olutasidenib. Topline data typically follows completion by weeks to months.
SourceOlutasidenib Phase 2 Est. Readout
Estimated primary completion for Olutasidenib trial (NCT06566742) in Myelodysplastic Syndromes. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Fostamatinib disodium
Immune Thrombocytopenic Purpura
fostamatinib
Lymphoma
Fostamatinib disodium (R935788)
Rheumatoid Arthritis
R906289 Monosodium (R289 Na)
Low Risk Myelodysplastic Syndromes
R940343
Asthma
R348 Ophthalmic
Keratoconjunctivitis Sicca
Olutasidenib + TMZ
High Grade Glioma
R932333
Lupus Erythematosus, Discoid
R926112
Rhinitis, Allergic, Seasonal
Olutasidenib
Targeted Therapy
Decitabine/cedazuridine
Mutant IDH1 Inhibitor Olutasidenib
Fostamatinib Disodium/R935788
Purpura, Thrombocytopenic, Idiopathic
Cladribine (CLAD)
Targeted Therapy
R788
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fostamatinib disodium | Phase 3 | Immune Thrombocytopenic Purpura | - | - |
fostamatinib | Phase 3 | Lymphoma | - | - |
Fostamatinib disodium (R935788) | Phase 2 | Rheumatoid Arthritis | - | - |
R906289 Monosodium (R289 Na) | Phase 2 | Low Risk Myelodysplastic Syndromes | - | - |
R940343 | Phase 2 | Asthma | - | - |
R348 Ophthalmic | Phase 2 | Keratoconjunctivitis Sicca | - | - |
Olutasidenib + TMZ | Phase 2 | High Grade Glioma | - | - |
R932333 | Phase 2 | Lupus Erythematosus, Discoid | - | - |
R926112 | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
Olutasidenib | Phase 2 | Targeted Therapy | - | - |
Decitabine/cedazuridine | Phase 2 | Mutant IDH1 Inhibitor Olutasidenib | - | - |
Fostamatinib Disodium/R935788 | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | - | - |
Cladribine (CLAD) | Phase 2 | Targeted Therapy | - | - |
R788 | Phase 2 | Rheumatoid Arthritis | - | - |
breast cancer
1 drug in this indication
ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer (2L+)
1 drug in this indication
ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in RIGEL PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 14 drug candidates in RIGEL PHARMACEUTICALS INC's (RIGL) pipeline across Phase 3, Phase 2. Its lead program is fostamatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RIGEL PHARMACEUTICALS INC's next FDA catalyst?→
RIGEL PHARMACEUTICALS INC's (RIGL) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RIGL biotech catalysts?→
Add RIGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RIGEL PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.